The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication

被引:1
|
作者
Guigues, Adeline [1 ]
Gimenez, Sandrine [1 ]
Mettling, Clement [1 ]
Maurel, Damien [2 ]
Doumazane, Etienne [3 ,4 ,7 ]
Prezeau, Laurent [3 ,4 ]
Francois, Vincent [1 ]
Corbeau, Pierre [1 ,5 ,6 ]
机构
[1] Univ Montpellier UMR9002, CNRS, Inst Genet Humaine, Montpellier, France
[2] Univ Montpellier I, ARPEGE Pharmacol Screening Interactome Platform Fa, Montpellier, France
[3] Univ Montpellier I, Inst Genom Fonct, CNRS UMR5203, INSERM U661, Montpellier, France
[4] Univ Montpellier 2, Montpellier, France
[5] Univ Montpellier, Montpellier, France
[6] CHU Caremeau, UF Immunol, Nimes, France
[7] Sorbonne Univ, Paris Brain Inst ICM, INSERM U1127, CNRS UMR7225, Paris, France
关键词
CCR5; dimerization; G protein-coupled receptors; HIV-1; entry; transcription; reverse transcription; IMMUNODEFICIENCY-VIRUS TYPE-1; CHOLESTEROL METABOLITES; OPIOID RECEPTORS; HETERODIMERIZATION; OXYSTEROLS; MIGRATION; DENSITY; ACTIVATION; GENERATION; EFFICIENCY;
D O I
10.1097/QAD.0000000000003931
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: CCR5, a G protein-coupled receptor (GPCR), is used by most HIV strains as a coreceptor. In this study, we looked for other GPCR able to modify HIV-1 infection. Design:We analyzed the effects of one GPCR coexpressed with CCR5, EBI2, on HIV-1 replicative cycle. Methods: We identified GPCR expressed in primary CD4(+)CCR5(+) T cells by multi-RT-qPCR. We studied GPCR dimerization by FRET technology. Cell lines expressing EBI2 were established by transduction with HIV vectors. HIV-1 entry was quantified with virions harboring beta-lactamase fused to the viral protein vpr, early and late HIV-1 transcriptions by qPCR, NFkB nuclear activation by immunofluorescence and transfection, and viral production by measuring p24 concentration in culture supernatant by ELISA. Results: We showed that EBI2 is naturally expressed in primary CD4(+)CCR5(+) T cells, and that CCR5 and EBI2 heterodimerize. We observed that this coexpression reduced viral entry by 50%. The amount of HIV reverse transcripts was similar in cells expressing or not EBI2. Finally, the presence of EBI2 induced the translocation of NFkB and activated HIV-1 genome expression. Globally, the result was a drastic HIV-1 R5, but not X4, overproduction in EBI2-transduced cells. Conclusion:EBI2 expression in CD4(+)CCR5(+) cells boosts HIV-1 R5 productive infection. As the natural ligand for EBI2 is present in blood and lymphoid tissues, the constant EBI2 activation might increase HIV replication in CD4(+) T cells. It might be of interest to test the effect of EBI2 antagonists on the residual viral production persisting in patients aviremic under treatment.
引用
收藏
页码:1449 / 1459
页数:11
相关论文
共 50 条
  • [31] Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Latinovic, Olga
    Le, Nhut
    Reitz, Marvin
    Pal, Ranajit
    DeVico, Anthony
    Foulke, James S.
    Redfield, Robert R.
    Heredia, Alonso
    AIDS, 2011, 25 (09) : 1232 - 1235
  • [32] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [33] Higher CCR5 density on CD4+ T-cells in mothers and infants is associated with increased risk of in-utero HIV-1 transmission
    Shalekoff, Sharon
    Dias, Bianca Da Costa
    Loubser, Shayne
    Strehlau, Renate
    Kuhn, Louise
    Tiemessen, Caroline T.
    AIDS, 2024, 38 (07) : 945 - 954
  • [34] High CCR5 Density on Central Memory CD4+ T Cells in Acute HIV-1 Infection Is Mostly Associated with Rapid Disease Progression
    Yang, Xue
    Jiao, Yan-mei
    Wang, Rui
    Ji, Yun-xia
    Zhang, Hong-wei
    Zhang, Yong-hong
    Chen, De-xi
    Zhang, Tong
    Wu, Hao
    PLOS ONE, 2012, 7 (11):
  • [35] Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5)
    Ruff, MR
    Melendez-Guerrero, LM
    Yang, QE
    Ho, WZ
    Mikovits, JW
    Pert, CB
    Ruscetti, FA
    ANTIVIRAL RESEARCH, 2001, 52 (01) : 63 - 75
  • [36] Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
    Visseaux, Benoit
    Charpentier, Charlotte
    Collin, Gilles
    Bertine, Melanie
    Peytavin, Gilles
    Damond, Florence
    Matheron, Sophie
    Lefebvre, Eric
    Brun-Vezinet, Francoise
    Descamps, Diane
    PLOS ONE, 2015, 10 (08):
  • [37] Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection
    Didigu, Chuka A.
    Wilen, Craig B.
    Wang, Jianbin
    Duong, Jennifer
    Secreto, Anthony J.
    Danet-Desnoyers, Gwenn A.
    Riley, James L.
    Gregory, Phillip D.
    June, Carl H.
    Holmes, Michael C.
    Doms, Robert W.
    BLOOD, 2014, 123 (01) : 61 - 69
  • [38] Cenicriviroc, a novel CCR5 (R5) and CCR2 antagonist, shows in vitro activity against R5 tropic HIV-2 clinical isolates
    Visseaux, B. F.
    Charpentier, C.
    Bertine, M.
    Peytavin, G.
    Damond, F.
    Matheron, S.
    Lefebvre, E.
    Brun-Vezinet, F.
    Descamps, D.
    ANTIVIRAL THERAPY, 2014, 19 : A115 - A115
  • [39] A Novel Small-molecule CCR5 Agonist, ESN-196, with Potent R5 HIV-1 Activity
    Ferain, Thierry
    Schols, Dominique
    Bernard, Jerome
    Fraser, Graeme
    ANTIVIRAL RESEARCH, 2009, 82 (02) : A23 - A24
  • [40] FENOFIBRATE MODULATES THE EXPRESSION OF THE CCR5 RECEPTOR IN CD4+T CELLS: POTENTIAL IMPLICATIONS FOR HIV
    Odeniyi, B. K.
    Farris, R. A.
    Stolarz, A. J.
    Wiley, C. A.
    Price, E. T.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S104 - S105